FG
CLBT icon

Formula Growth’s Cellebrite CLBT Stock Holding History

Formula Growth’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
70,000
+20,000
+40% +$264K 0.36% 103
2026
Q1 		$689K Buy
+50,000
New +$754K 0.31% 104

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Formula Growth's CLBT Position: Q2 2026 in Review

Formula Growth increased its Cellebrite (CLBT) stake by 40% in Q2 2026, buying an estimated $264K and bringing the position to 70,000 shares worth $1.02M. The position accounts for 0.36% of the portfolio, ranked #103.

Formula Growth first reported a position in CLBT in Q1 2026 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Formula Growth held 70,000 shares of Cellebrite worth $1.02M as of Q2 2026.
  • Formula Growth bought 20,000 Cellebrite shares in Q2 2026, an estimated $264K.
  • Cellebrite made up 0.36% of Formula Growth's portfolio in Q2 2026, its #103 holding.
  • Formula Growth first reported a position in Cellebrite in Q1 2026 and has held it in 2 quarters since.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Formula Growth's 13F filing for Q2 2026, filed 17 Aug 2026.